Answer to: “Biomarkers in Allergic Asthma: Which Matrix Should We Use?”

We appreciate comments from Dr. M. Maniscalco and A. Motta on our review article [1]. The comments made on the matter about which biological matrix(ces) should be used in the quest of biomarkers in allergic asthma are well accepted. However, we would like to open the discussion about the topics exposed by the authors. Definitely, asthma is a very complex disease which presents heterogeneous clinical symptoms and multiple causes. Presenting diverse sub-phenotypes, to date there is not enough information to characterize them in the clinical setting [2, 3]. This article is protected by copyright. All rights reserved.